46 results
Page 2 of 3
8-K
EX-10.1
gij hj4i90v1p2
1 Jun 21
Entry into a Material Definitive Agreement
9:02am
8-K
EX-99.1
4p4j tjsp
17 May 21
Baudax Bio Announces Publication of Phase IIIb ANJESO® Data in the Journal Pain Management
4:10pm
8-K
EX-99.1
lyihhlhqa
26 Apr 21
Other Events
4:06pm
8-K
EX-10.1
ncjihkq0r8rr00
9 Feb 21
Entry into a Material Definitive Agreement
5:11pm
8-K
EX-99.1
glr g7w7owm
5 Jan 21
Other Events
8:05am
8-K
EX-10.1
pwvwx36l3en5d ws5
18 Dec 20
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.1
srq7c
24 Nov 20
Entry into a Material Definitive Agreement
6:07am
8-K
EX-99.1
crxhj5
20 Oct 20
Baudax Bio Provides Commercial and Corporate Update
7:30am
8-K
EX-99.1
lrugs07 h1w
22 Sep 20
Other Events
7:00am
8-K
EX-99.2
7i3knk
10 Aug 20
Baudax Bio Reports Second Quarter 2020 Financial Results
7:01am
8-K
EX-99.1
mdkzgv9d la2
20 Jul 20
Other Events
7:40am
8-K
EX-99.1
pt7qe7y93p2
15 Jun 20
Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of UniqueC-Code and Pass-Through Payment Status
8:37am
8-K
EX-10.1
w77k4yw1bi3
2 Jun 20
Entry into a Material Definitive Agreement
7:45am
8-K
EX-1.1
5ak8o
24 Mar 20
Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants
9:33am
8-K
EX-99.1
cftr8r5 42
21 Feb 20
Other Events
9:27am
8-K
EX-99.2
j6p0rh
20 Feb 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
smo05m
20 Feb 20
Regulation FD Disclosure
5:29pm
10-K
EX-10.29
ucbx da2v
13 Feb 20
Annual report
5:05pm
10-K
d4ik9 t10hmhi7qalc3
13 Feb 20
Annual report
5:05pm